Ongoing phase I trials are investigating the efficacy of the CDK7 inhibitors SY-1365 and CT-7001 combined with fulvestrant in patients with solid tumors, including ER+/HER2− breast cancer patients who progressed on CDK4/6i-based therapy (NCT03134638, and NCT03363893). This evidence concerns the gene CDK4 and breast cancer.